Literature DB >> 15986135

Bone morphogenetic proteins in melanoma: angel or devil?

Mei-Yu Hsu1, Sherry Rovinsky, Sunita Penmatcha, Meenhard Herlyn, Desirae Muirhead.   

Abstract

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta (TGF-beta) superfamily serving multiple functions in many cell and tissue types including proliferation, apoptosis, differentiation, chemotaxis, angiogenesis, and matrix production during embryogenic development as well as in adult life. Despite the tremendous progress in delineating functional derangements of BMP pathways in carcinogenesis during the last decade, the biological significance of BMPs in human melanoma has received very little attention. It is now clear that biological responses to BMPs are cell type-specific and divergent effects, i.e., both oncogenic and tumor suppressor activities, have been described. Thus, knowledge generated in one system may not translate directly to another. In this review, we summarize the current understanding of BMP signaling in various human cancers and discuss original data pertaining to cutaneous melanoma obtained in our laboratory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986135     DOI: 10.1007/s10555-005-1575-y

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  27 in total

Review 1.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

2.  Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.

Authors:  George S Karagiannis; Aaron Berk; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2013-04-18       Impact factor: 6.603

3.  MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma.

Authors:  Simone Braig; Daniel W Mueller; Tanja Rothhammer; Anja-Katrin Bosserhoff
Journal:  Cell Mol Life Sci       Date:  2010-05-18       Impact factor: 9.261

4.  SMAD signaling promotes melanoma metastasis independently of phenotype switching.

Authors:  Eylul Tuncer; Raquel R Calçada; Daniel Zingg; Sandra Varum; Phil Cheng; Sandra N Freiberger; Chu-Xia Deng; Ingo Kleiter; Mitchell P Levesque; Reinhard Dummer; Lukas Sommer
Journal:  J Clin Invest       Date:  2019-04-30       Impact factor: 14.808

Review 5.  Regulation of tumor cell dormancy by tissue microenvironments and autophagy.

Authors:  Maria Soledad Sosa; Paloma Bragado; Jayanta Debnath; Julio A Aguirre-Ghiso
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 6.  Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.

Authors:  Pawina Jiramongkolchai; Philip Owens; Charles C Hong
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

7.  Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation.

Authors:  Mei-Yu Hsu; Sherry A Rovinsky; Chiou-Yan Lai; Shadi Qasem; Xiaoming Liu; Joan How; John F Engelhardt; George F Murphy
Journal:  Lab Invest       Date:  2008-06-16       Impact factor: 5.662

8.  Bone morphogenetic protein signaling: implications in urology.

Authors:  Jeongyun Jeong; Dong Il Kang; Geun Taek Lee; Isaac Yi Kim
Journal:  Korean J Urol       Date:  2010-08-18

Review 9.  Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

Authors:  Michael P O'Connell; Ashani T Weeraratna
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-25       Impact factor: 4.693

10.  A human bone morphogenetic protein antagonist is down-regulated in renal cancer.

Authors:  Kimberly Rose Blish; Wei Wang; Mark C Willingham; Wei Du; Charles E Birse; Surekha R Krishnan; Julie C Brown; Gregory A Hawkins; A Julian Garvin; Ralph B D'Agostino; Frank M Torti; Suzy V Torti
Journal:  Mol Biol Cell       Date:  2007-11-21       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.